Evaluation of Infliximab and Anti-infliximab LISA-TRACKER Immunoassays for the Therapeutic Drug Monitoring of SB2 Infliximab Biosimilar

被引:10
|
作者
Jentzer, Alexandre [1 ]
Berger, Anne-Emmanuelle [1 ]
Labetoulle, Remi [1 ]
Haccourt, Alice [1 ]
Roblin, Xavier [2 ]
Paul, Stephane [1 ]
机构
[1] Hosp St Etienne, Lab Immunol & Immunomonitoring, Clin Invest Ctr, Inserm 1408,GIMAP EA3064, St Etienne, France
[2] Hosp St Etienne, Hepatol Enterol Gastrol Dept, Clin Invest Ctr, Inserm 1408,GIMAP EA3064, St Etienne, France
关键词
anti-TNF alpha; infliximab biosimilar; SB2; Flixabi; DOUBLE-BLIND; INNOVATOR INFLIXIMAB; PARALLEL-GROUP; SAFETY; CT-P13; EFFICACY; MULTICENTER; PLACE;
D O I
10.1097/FTD.0000000000000565
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background: SB2, an infliximab (IFX) biosimilar to the reference infliximab (R.I.) product (Remicade), received approval in the European Union for all IFX indications. Many decision algorithms based on the measurement of IFX trough levels and antibodies to infliximab are being increasingly used to optimize IFX treatment. The aim of our study was to evaluate whether the biosimilar SB2 could be efficiently monitored using the LISA-TRACKER IFX and anti-IFX assays developed by Theradiag (Croissy Beaubourg, France). Methods: Standard curves of R.I. and SB2 were compared, and then accuracy of the LISA-TRACKER IFX assay in detecting the spiked concentration of SB2 was measured. Levels of IFX from SB2 spiked samples and R.I. clinical samples were calculated. Intra-run and inter-run imprecision were also measured with SB2 spiked samples. The ability of polyclonal antibodies directed against R.I. to block the detection of SB2 using the LISA-TRACKER IFX assay and the capacity of SB2 to block the detection of anti-R.I. antibodies using the LISA-TRACKER anti-IFX assay were tested. Results: Twelve patients treated with SB2 including 2 patients with SB2-specific antibodies were measured with the LISA-TRACKER anti-IFX assay. We demonstrated that the LISA-TRACKER assay is suitable for the quantification of SB2 in human serum samples. The percentage of recovery was between 82% and 113%. High intra-run and inter-run imprecisions were obtained with the LISA-TRACKER infliximab assay for the quantification of SB2 (SD ranged from 3.3% to 17.9%). The SB2-blocking capacity of R.I. polyclonal antibodies in spiked samples was demonstrated with inhibition between 80% and 97%. SB2 trough levels and anti-SB2 antibodies have also been confirmed in SB2-treated patients. Conclusions: LISA-TRACKER IFX and anti-IFX assays are suitable for the monitoring of patients treated with SB2.
引用
收藏
页码:749 / 753
页数:5
相关论文
共 50 条
  • [1] Therapeutic drug monitoring of infliximab biosimilar and anti-infliximab antibodies in inflammatory diseases
    Elberdin, Laida
    Outeda, Maria
    Mateos, Maria
    Martinez, Cristina
    Salvador, Pilar
    Angeles Porta, Maria
    Isabel Martin, Maria
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2017, 39 (01) : 338 - 339
  • [2] SB2: An Infliximab Biosimilar
    Lamb, Yvette N.
    Scott, Lesley J.
    Deeks, Emma D.
    [J]. BIODRUGS, 2017, 31 (05) : 461 - 464
  • [3] SB2: An Infliximab Biosimilar
    Yvette N. Lamb
    Lesley J. Scott
    Emma D. Deeks
    [J]. BioDrugs, 2017, 31 : 461 - 464
  • [4] Therapeutic Drug Monitoring of the Biosimilar SB2 (RENFLEXIS™, Infliximab-abda) Using LabCorp Infliximab Assays for Drug Level and Anti-drug Antibodies
    Kelly, Chun
    Zonia, Garcia Gonzalez
    Jane, Yang
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2018, 113 : S25 - S25
  • [5] Serum trough infliximab and anti-infliximab antibodies in a cohort of gastroenterology and rheumatology patients' infliximab therapeutic drug monitoring
    Barlow, Nicola L.
    Mohammed, Pervaz
    Berg, Jonathan D.
    [J]. ANNALS OF CLINICAL BIOCHEMISTRY, 2016, 53 (04) : 477 - 484
  • [6] EVALUATION OF PHARMACOKINETIC PROFILES OF SB2 AS A BIOSIMILAR OF REFERENCE INFLIXIMAB
    Shin, Donghoon
    Kang, Jung Won
    Park, Sunghoon
    Lee, Younju
    Lee, Sora
    [J]. GASTROENTEROLOGY, 2017, 152 (05) : S589 - S589
  • [7] Evaluation of pharmacokinetic profiles of SB2 as a biosimilar of reference infliximab
    Shin, D.
    Kang, J. W.
    Park, S.
    Lee, Y.
    Lee, S.
    [J]. JOURNAL OF CROHNS & COLITIS, 2017, 11 : S277 - S278
  • [8] Therapeutic drug monitoring countering the effect of anti-infliximab antibodies
    Hooijberg, Femke
    Wolbink, Gertjan
    [J]. LANCET RHEUMATOLOGY, 2024, 6 (04): : e193 - e194
  • [9] The new biosimilar of infliximab SB2 can be quantified by IFX-optimised therapeutic drug monitoring assays
    Magro, F.
    Rocha, C.
    Vieira, A. I.
    Sousa, H. T.
    Rosa, I.
    Lopes, S.
    Carvalho, J.
    Dias, C. C.
    Afonso, J.
    [J]. JOURNAL OF CROHNS & COLITIS, 2018, 12 : S216 - S216
  • [10] Development and evaluation of i-TRACKER infliximab and i-TRACKER anti-Infliximab kits: fast and innovative chemiluminescent assays for the monitoring of patients treated with infliximab
    Noguier, G.
    Montaillier, C.
    Daviere, S.
    Colombeau, L.
    Parussini, E.
    [J]. JOURNAL OF CROHNS & COLITIS, 2020, 14 : S563 - S563